Clinical Trial News and Research

RSS

Bioactive compounds in coffee may prevent prostate cancer recurrence, delay progression

Coffee consumption is associated with a lower risk of prostate cancer recurrence and progression, according to a new study by Fred Hutchinson Cancer Research Center scientists that is online ahead of print in Cancer Causes & Control.

27 Aug 2013

Sangamo BioSciences signs definitive agreement to buy Ceregene

Sangamo BioSciences, Inc. announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus gene therapies.

26 Aug 2013

Laureate Biopharma collaborates with Dyax to develop new treatment candidate for HAE

Laureate Biopharma is pleased to announce its successful collaboration with Dyax Corp. for process development and cGMP production of a new treatment candidate for hereditary angioedema.

26 Aug 2013

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for the orphan drug VALCHLOR (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

26 Aug 2013

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Immune Pharmaceuticals Inc. announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation.

26 Aug 2013

Screening strategy for ovarian cancer appears to be highly specific for detecting disease at early stages

A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal. The strategy is described in a study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. If verified in an ongoing clinical trial, it could potentially help save the lives of thousands of women each year in the United States alone.

26 Aug 2013

BESTCILIA project aims to improve screening, treatment of Primary Ciliary Dyskinesia

Primary Ciliary Dyskinesia is mainly a lung disease: a rare, genetically heterogeneous disorder resulting from dysfunction of small hair-like organelles (cilia) that clean the upper and lower airways. It can also affect multiple organs beside the respiratory system, and may cause serious impairment and lower quality of life. Its prevalence is estimated to be about 1 in 16,000.

26 Aug 2013

Early antiretroviral therapy treatment benefits HIV-infected infants

Giving antiretroviral therapy immediately after diagnosis for a limited period of time is more beneficial than postponing treatment in young infants infected with HIV, slowing progression of the disease and delaying the time to starting long-term ART, according to new research published in The Lancet.

23 Aug 2013

Moffitt Cancer Center study could offer hope to melanoma sufferers

A new study at Moffitt Cancer Center could offer hope to people with melanoma, the deadliest form of skin cancer. Researchers are investigating whether an injectable known as PV-10 can shrink tumors and reduce the spread of cancer.

23 Aug 2013

Drug to treat blood cancers may also stop spread of invasive breast cancer

A drug used to treat blood cancers may also stop the spread of invasive breast cancer, researchers at Mayo Clinic in Florida have discovered. Their study, published online in Breast Cancer Research, found that in the lab and in animals, the drug decitabine turns on a gene coding for protein kinase D1 (PRKD1) that halts the ability of cancer cells to separate from a tumor and spread to distant organs.

23 Aug 2013

Caris Life Sciences to facilitate patient access to tumour profiling service in Middle East and Africa

Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of personalized medicine in oncology, has signed a distribution agreement with IPS Genomix to facilitate patient access to its tumour profiling service, Molecular Intelligence, in select Middle Eastern and African markets.

22 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

MicuRx Pharmaceuticals raises $25 million in Series B financing

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures.

22 Aug 2013

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.

22 Aug 2013

Majority of Alzheimer's researchers support disclosure of results to study participants

A leading group of Alzheimer's researchers contends that, as biomarkers to detect signals of the disease improve at providing clinically meaningful information, researchers will need guidance on how to constructively disclose test results and track how disclosure impacts both patients and the data collected in research studies.

22 Aug 2013

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has initiated patient recruitment for a new clinical trial of its orally ingestible insulin capsule, ORMD-0801 for patients with type 1 diabetes mellitus in Israel.

22 Aug 2013

Radiation Oncologist receives Young Investigator Award from PCF

Jefferson Radiation Oncologist, Nicole Simone, M.D., was recently awarded one of 21 Young Investigator Awards from the Prostate Cancer Foundation (PCF).

21 Aug 2013

NIH awards grant to FDA-approved clinical trial of auditory brainstem implant in children

House Research Institute (HRI) and Children's Hospital Los Angeles Children's Hospital) announced today final approval of grant funding by the National Institutes of Health (NIH) National Institute on Deafness and Communications Disorders (NIDCD) for a major five-year, FDA-approved clinical trial of the auditory brainstem implant (ABI) in children.

21 Aug 2013

Study shows continuous CSF drainage is associated with complications in patients with SAH

Researchers at Duke University conducted a randomized clinical trial in patients with subarachnoid hemorrhage (SAH). In this study, the researchers compared two approaches to intracranial pressure management-continuous and intermittent drainage of cerebrospinal fluid (CSF)-and outcomes associated with those methods, focusing specifically on the incidence of cerebral vasospasm.

21 Aug 2013

Clinical Trial News and Research

Bioactive compounds in coffee may prevent prostate cancer recurrence, delay progression

Sangamo BioSciences signs definitive agreement to buy Ceregene

Laureate Biopharma collaborates with Dyax to develop new treatment candidate for HAE

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Screening strategy for ovarian cancer appears to be highly specific for detecting disease at early stages

BESTCILIA project aims to improve screening, treatment of Primary Ciliary Dyskinesia

Early antiretroviral therapy treatment benefits HIV-infected infants

Moffitt Cancer Center study could offer hope to melanoma sufferers

Drug to treat blood cancers may also stop spread of invasive breast cancer

Caris Life Sciences to facilitate patient access to tumour profiling service in Middle East and Africa

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

MicuRx Pharmaceuticals raises $25 million in Series B financing

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Majority of Alzheimer's researchers support disclosure of results to study participants

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

Radiation Oncologist receives Young Investigator Award from PCF

NIH awards grant to FDA-approved clinical trial of auditory brainstem implant in children

Study shows continuous CSF drainage is associated with complications in patients with SAH

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer